April 17 (Reuters) - Eli Lilly's ( LLY ) newly launched
obesity pill was prescribed 1,390 times in the U.S. as of the
week ended April 10, according to an analyst who cited IQVIA
data.
Novo Nordisk's oral Wegovy had hit 3,071 U.S.
prescriptions in the first four days after its launch on January
5.